IQV vs RPRX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
IQVIA exhibits strong fundamental health with a Piotroski F-Score of 7/9 and a highly attractive PEG ratio of 0.68, suggesting significant undervaluation relative to its growth. While the stock is currently trading at a premium to its Graham Number ($82.24), it sits well below its intrinsic value ($231.28) and analyst targets ($231.60). However, the bullish fundamental outlook is contrasted by a severe technical downtrend and liquidity concerns, evidenced by a current ratio of 0.75 and high leverage. Overall, the company's robust ROE and consistent earnings growth make it a strong value play despite short-term price volatility.
RPRX exhibits a stable but mediocre Piotroski F-Score of 4/9, indicating average financial health without strong momentum. The stock is significantly overvalued, trading at $50.00 despite a Graham Number of $24.60 and an Intrinsic Value of $36.49. Aggressive insider selling by the CFO and a sharp decline in recent Q/Q EPS growth (-67.5%) signal significant internal caution. While analyst sentiment remains a 'buy', the deterministic data and valuation gap suggest a high risk of a price correction.
Compare Another Pair
Related Comparisons
IQV vs RPRX: Head-to-Head Comparison
This page compares IQVIA Holdings Inc. (IQV) and Royalty Pharma plc (RPRX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.